Cidofovir

( S) - [ 1 - (4 -amino-2 -oxo- pyrimidin- 1-yl) -3-hydroxy -propan- 2-yl ] oxy - methylphosphonic

J05AB12

Antivirals

260 ° C

Risk

Template: Infobox chemical / molecular formula search available

Cidofovir (trade name Vistide ®, manufactured by Gilead Sciences ) is an acyclic nucleotide analog ( monophosphate ) of deoxycytidine monophosphate and belongs to the group of antivirals. Inhibits viral DNA polymerase of many DNA viruses. Cidofovir has been approved for the intravenous treatment caused by the cytomegalovirus retinitis in AIDS patients. Efficacy in other viral diseases has not been established.

On various cream formulations of cidofovir have been used experimentally for the control of HPV infections. However, all strains of HPV not have their own DNA polymerase, for this reason, the exact mechanism of action of cidofovir in HPV infections, is still unclear. In vitro, cidofovir led to apoptosis of HPV -positive keratinocytes. In various studies with few patients, the local administration of one percent cream or gel resulted in condylomata acuminata for reduction or for complete healing in about 50 percent of treated patients. For treatment-refractory multiple common warts or plantar warts were reported in individual case reports and in a small study of one or three percent cidofovir cream cure rates of 90 to 100 percent. Systemic side effects of cidofovir were not observed, but there were often local irritation. In patients after lung transplantation cidofovir could lead to acute renal failure.

Vistide is not expressly indicated for intraocular injection or topical application. Background for an appropriate information are reports of adverse events such as nephrotoxicity, neutropenia, and toxic effects on the eye in connection with unapproved forms of application as well as application in non-approved indications.